These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15858853)

  • 1. Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration.
    Das D; Lin S
    J Pharm Sci; 2005 Jun; 94(6):1343-53. PubMed ID: 15858853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity.
    Olivier JC; Fenart L; Chauvet R; Pariat C; Cecchelli R; Couet W
    Pharm Res; 1999 Dec; 16(12):1836-42. PubMed ID: 10644071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles.
    Kreuter J; Ramge P; Petrov V; Hamm S; Gelperina SE; Engelhardt B; Alyautdin R; von Briesen H; Begley DJ
    Pharm Res; 2003 Mar; 20(3):409-16. PubMed ID: 12669961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Transport of the hexapeptide dalargin across the hemato-encephalic barrier into the brain using polymer nanoparticles].
    Aliautdin RN; Petrov VE; Ivanov AA; Kreuter J; Kharkevich DA
    Eksp Klin Farmakol; 1996; 59(3):57-60. PubMed ID: 8974587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro.
    Alyaudtin RN; Reichel A; Löbenberg R; Ramge P; Kreuter J; Begley DJ
    J Drug Target; 2001 Jun; 9(3):209-21. PubMed ID: 11697206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of apolipoproteins on dalargin transport across the blood-brain barrier.
    Shamenkov DA; Petrov VE; Alyautdin RN
    Bull Exp Biol Med; 2006 Dec; 142(6):703-6. PubMed ID: 17603675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections.
    Schröder U; Sabel BA
    Brain Res; 1996 Feb; 710(1-2):121-4. PubMed ID: 8963650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle technology for delivery of drugs across the blood-brain barrier.
    Schroeder U; Sommerfeld P; Ulrich S; Sabel BA
    J Pharm Sci; 1998 Nov; 87(11):1305-7. PubMed ID: 9811481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of oral dalargin-loaded nanoparticle delivery across the blood-brain barrier.
    Schroeder U; Sommerfeld P; Sabel BA
    Peptides; 1998; 19(4):777-80. PubMed ID: 9622035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circadian phase-dependent antinociceptive reaction in mice determined by the hot-plate test and the tail-flick test after intravenous injection of dalargin-loaded nanoparticles.
    Ramge P; Kreuter J; Lemmer B
    Chronobiol Int; 1999 Nov; 16(6):767-77. PubMed ID: 10584177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved brain uptake and pharmacological activity of dalargin using a peptide-vector-mediated strategy.
    Rousselle C; Clair P; Smirnova M; Kolesnikov Y; Pasternak GW; Gac-Breton S; Rees AR; Scherrmann JM; Temsamani J
    J Pharmacol Exp Ther; 2003 Jul; 306(1):371-6. PubMed ID: 12682214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body distribution of 3H-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after i.v. injections to mice.
    Schroeder U; Schroeder H; Sabel BA
    Life Sci; 2000; 66(6):495-502. PubMed ID: 10794066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparative Study of Orally Delivered PBCA and ApoE Coupled BSA Nanoparticles for Brain Targeting of Sumatriptan Succinate in Therapeutic Management of Migraine.
    Girotra P; Singh SK
    Pharm Res; 2016 Jul; 33(7):1682-95. PubMed ID: 27003706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of surfactant on fabrication and characterization of paclitaxel-loaded polybutylcyanoacrylate nanoparticulate delivery systems.
    Mitra A; Lin S
    J Pharm Pharmacol; 2003 Jul; 55(7):895-902. PubMed ID: 12906746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease.
    Kulkarni PV; Roney CA; Antich PP; Bonte FJ; Raghu AV; Aminabhavi TM
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(1):35-47. PubMed ID: 20049829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery.
    Garcia-Fuentes M; Prego C; Torres D; Alonso MJ
    Eur J Pharm Sci; 2005 May; 25(1):133-43. PubMed ID: 15854809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(n-butylcyanoacrylate) nanoparticles for oral delivery of quercetin: preparation, characterization, and pharmacokinetics and biodistribution studies in Wistar rats.
    Bagad M; Khan ZA
    Int J Nanomedicine; 2015; 10():3921-35. PubMed ID: 26089668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
    Kreuter J; Shamenkov D; Petrov V; Ramge P; Cychutek K; Koch-Brandt C; Alyautdin R
    J Drug Target; 2002 Jun; 10(4):317-25. PubMed ID: 12164380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a chitosan-based nanoparticle formulation for delivery of a hydrophilic hexapeptide, dalargin.
    Chen Y; Siddalingappa B; Chan PH; Benson HA
    Biopolymers; 2008; 90(5):663-70. PubMed ID: 18655140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles.
    Alyautdin RN; Petrov VE; Langer K; Berthold A; Kharkevich DA; Kreuter J
    Pharm Res; 1997 Mar; 14(3):325-8. PubMed ID: 9098875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.